Lymphoma Clinical Trials & Research

Lymphoma Clinical Trials & Research

Share
Print
Share
Print
MSK’s Vision to Transform Lymphoma Treatment
Anas Younes, Chief of the Lymphoma Service, details MSK’s ambitious strategy for advancing lymphoma therapies.
Learn more

Our mission at MSK has always been to care for and cure people with cancer. As part of this goal, we’ve worked for decades to find new treatments. Many of our innovations and approaches have set the standard for care.

The MSK Lymphoma Service has one of the largest and most innovative clinical trial programs in the world. We offer a diverse range of treatment options for patients with Hodgkin and non-Hodgkin lymphoma. Because of our active clinical trial research program, we have helped to develop most of the lymphoma drugs that have improved patient outcomes and are currently FDA approved. Many of our clinical trials turn the latest discoveries from the laboratory into new treatments for patients with lymphoma.

Choosing MSK may give you access to new treatment options that are not yet readily available and could turn out to be tomorrow’s cures. We have extensive experience in matching patients with the clinical trials that will benefit them the most.


Marginal Zone Lymphoma
Follicular Lymphoma

Prior Treatment (Relapsed/Refractory)

A Phase I Study of PRT062070 in Patients with Persistent or Recurrent Chronic Lymphocytic Leukemia, Small Cell Lymphocytic Leukemia, or B-Cell Non-Hodgkin Lymphoma
Paul A. Hamlin
[Protocol 14-023]

A Phase I Study of BTCT4465A Immunotherapy in Patients with Recurrent or Persistent B-cell Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Matthew J. Matasar
[Protocol 16-182]

A Phase III Study of Standard Immunochemotherapy with and without Copanlisib in Patients with Recurrent Non-Hodgkin Lymphoma
Matthew J. Matasar
[Protocol 16-873]

A Phase I Study of ME-401 in Patients with Recurrent or Persistent Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia or Follicular Lymphoma
[Protocol 16-1614]

A Study of CA-4948 in Patients with Recurrent or Persistent Non-Hodgkin Lymphoma
Anas Younes
[Protocol 18-053]

A Phase I Study of AZD5991 in Patients with Recurrent or Persistent Hematologic Cancers
Neha S. Korde
[Protocol 18-117]

A Phase I Study of JNJ-67856633 for Patients with Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
Anas Younes
[Protocol 19-151]

A Phase I Study of AG-636 for Patients with Advanced Lymphoma
Gottfried von Keudell
[Protocol 19-183]

A Phase I Study of Pembrolizumab Immunotherapy and Umbralisib in Patients with Advanced B-Cell Non-Hodgkin Lymphoma
Gottfried von Keudell
[Protocol 19-203]

A Phase IA/IB Study of TTI-622 Immunotherapy in Patients with Advanced Persistent or Recurrent Non-Hodgkin or Hodgkin Lymphoma or Multiple Myeloma
Alexander M. Lesokhin
[Protocol 19-210]

A Phase III Study of Ibrutinib with Rituximab in People with Untreated Marginal Zone Lymphoma
Ariela Noy
[Protocol 19-243]

Chronic Lymphocytic Lymphoma (CLL)

Newly Diagnosed/Frontline Studies and Advanced Disease

A Phase II Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia
[Protocol 18-427]

Prior Treatment (Relapsed/Refractory)

A Phase I Study of BTCT4465A Immunotherapy in Patients with Recurrent or Persistent B-cell Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Matthew J. Matasar
[Protocol 16-182]

A Phase I Study of ME-401 in Patients with Recurrent or Persistent Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia or Follicular Lymphoma
[Protocol 16-1614]

A Phase I Study of AZD5991 in Patients with Recurrent or Persistent Hematologic Cancers
Neha S. Korde
[Protocol 18-117]

A Phase II Study of Pembrolizumab Immunotherapy, Ublituximab, and Umbralisib Given Together in Patients with Chronic Lymphocytic Leukemia
Anthony Mato
[Protocol 18-283]

A Phase I/II Study of LOXO-305 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Anthony Mato
[Protocol 19-077]

A Phase I Study of JNJ-67856633 for Patients with Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
Anas Younes
[Protocol 19-151]

A Phase IA/IB Study of TTI-622 Immunotherapy in Patients with Advanced Persistent or Recurrent Non-Hodgkin or Hodgkin Lymphoma or Multiple Myeloma
Alexander M. Lesokhin
[Protocol 19-210]

A Phase II Study of Ublituximab and Umbralisib in Combination with Ibrutinib or Venetoclax to Treat Chronic Lymphocytic Leukemia
Anthony Mato
[Protocol 19-225]

Small Lymphocytic Lymphoma (SLL)
Diffuse Large B-Cell Lymphoma

Newly Diagnosed/Frontline Studies and Advanced Disease

Prior Treatment (Relapsed/Refractory)

A Phase I Study of BTCT4465A Immunotherapy in Patients with Recurrent or Persistent B-cell Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Matthew J. Matasar
[Protocol 16-182]

A Phase I Study of ME-401 in Patients with Recurrent or Persistent Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia or Follicular Lymphoma
[Protocol 16-1614]

A Phase I Study of REGN3767 and/or REGN2810 Immunotherapy in Patients with Advanced Lymphoma
M. Lia Palomba
[Protocol 17-421]

A Phase I Study of AZD5991 in Patients with Recurrent or Persistent Hematologic Cancers
Neha S. Korde
[Protocol 18-117]

A Study of CA-4948 in Patients with Recurrent or Persistent Non-Hodgkin Lymphoma
Anas Younes
[Protocol 18-053]

A Phase II Study of CPI-613 for Patients with Recurrent or Persistent Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma with High-Risk Genetic Changes
Ariela Noy
[Protocol 18-443]

A Phase I Study of Abexinostat and Ibrutinib to Treat Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma
Gottfried von Keudell
[Protocol 19-080]

A Phase I Study of JNJ-67856633 for Patients with Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
Anas Younes
[Protocol 19-151]

A Phase I Study of AG-636 for Patients with Advanced Lymphoma
Gottfried von Keudell
[Protocol 19-183]

A Phase I Study of Pembrolizumab Immunotherapy and Umbralisib in Patients with Advanced B-Cell Non-Hodgkin Lymphoma
Gottfried von Keudell
[Protocol 19-203]

A Phase IA/IB Study of TTI-622 Immunotherapy in Patients with Advanced Persistent or Recurrent Non-Hodgkin or Hodgkin Lymphoma or Multiple Myeloma
Alexander M. Lesokhin
[Protocol 19-210]

A Phase III Study of Polatuzumab Vedotin Combined with Rituximab, Gemcitabine, and Oxaliplatin in People with Diffuse Large B-Cell Lymphoma
Matthew J. Matasar
[Protocol 20-031]

Hodgkin Lymphoma
Mantle Cell Lymphoma
T-cell Lymphoma: PTCL, CTCL and Extranodal NK nasal type

Newly Diagnosed/Frontline Studies and Advanced Disease

A Pilot Study of Pembrolizumab Immunotherapy in Patients with Extranodal NK/T-cell Nasal-Type Lymphoma
Alison J. Moskowitz
[Protocol 18-393] NK T cell only

A Phase II Study of CC-486 plus Standard Chemotherapy (CHOP) for Patients with Previously Untreated Peripheral T-Cell Lymphoma
Alison J. Moskowitz
[Protocol 19-086] PTCL only

Prior Treatment (Relapsed/Refractory)

A Phase I Study of PRT062070 in Patients with Persistent or Recurrent Chronic Lymphocytic Leukemia, Small Cell Lymphocytic Leukemia, or B-Cell Non-Hodgkin Lymphoma
Paul A. Hamlin
[Protocol 14-023]

A Phase I Study of Duvelisib with Either Romidepsin or Bortezomib for Recurrent or Persistent T-Cell Lymphoma
Steven M. Horwitz
[Protocol 16-042]

A Phase I Study of TTI-621Immunotherapy in Patients with Persistent or Recurrent Blood Cancers
Steven M. Horwitz
[Protocol 16-1347]

A Phase I Study of MRG-106 in Patients with Various Recurrent or Persistent Lymphomas and Leukemias
Alison J. Moskowitz
[Protocol 18-082] PTCL only

A Phase I Study of AZD5991 in Patients with Recurrent or Persistent Hematologic Cancers
Neha S. Korde
[Protocol 18-117]

A Phase II Study to Determine the Optimal Dose of Brentuximab Vedotin for Mycosis Fungoides and Lymphomatoid Papulosis
Alison J. Moskowitz
[Protocol 18-147]

A Phase II Study of Duvelisib in Patients with Recurrent or Persistent Peripheral T-Cell Lymphoma
Steven M. Horwitz
[Protocol 18-377] PTCL only

A Phase I Study of AG-636 for Patients with Advanced Lymphoma
Gottfried von Keudell
[Protocol 19-183]

A Phase IA/IB Study of TTI-622 Immunotherapy in Patients with Advanced Persistent or Recurrent Non-Hodgkin or Hodgkin Lymphoma or Multiple Myeloma
Alexander M. Lesokhin
[Protocol 19-210] CTCL only

Burkitt Lymphoma
HIV+ Lymphoma
Waldenstrom’s Macroglobulinemia